Literature DB >> 9755901

Automated covariate model building within NONMEM.

E N Jonsson1, M O Karlsson.   

Abstract

PURPOSE: One important task in population pharmacokinetic/pharmacodynamic model building is to identify the relationships between the parameters and demographic factors (covariates). The purpose of this study is to present an automated procedure that accomplishes this. The benefits of the proposed procedure over other commonly used methods are (i) the covariate model is built for all parameters simultaneously, (ii) the covariate model is built within the population modeling program (NONMEM) giving familiar meaning to the significance levels used, (iii) it can appropriately handle covariates that varies over time and (iv) it is not dependent on the quality of the posterior Bayes estimates of the individual parameter values. For situations in which the computer run-times are a limiting factor, a linearization of the non-linear mixed effects model is proposed and evaluated.
METHODS: The covariate model is built in a stepwise fashion in which both linear and non-linear relationships between the parameters and covariates are considered. The linearization is basically a linear mixed effects model in which the population predictions and their derivatives with respect to the parameters are fixed from a model without covariates. The stepwise procedure as well as the linearization was evaluated using simulations in which the covariates were taken from a real data set.
RESULTS: The covariate models identified agreed well with what could be expected based on the covariates that were actually supported in each of the simulated data sets. The predictive performance of the linearized model was close to that of the non-linearized model.
CONCLUSIONS: The proposed procedure identifies covariate models that are close to the model supported by the data set as well as being useful in the prediction of new data. The linearized model performs nearly as well as the non-linearized model.

Mesh:

Year:  1998        PMID: 9755901     DOI: 10.1023/a:1011970125687

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  8 in total

1.  Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.

Authors:  J W Mandema; D Verotta; L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1992-10

2.  A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam.

Authors:  P O Maitre; M Bührer; D Thomson; D R Stanski
Journal:  J Pharmacokinet Biopharm       Date:  1991-08

3.  A pooled analysis of CD4 response to zidovudine and zalcitabine treatment in patients with AIDS and AIDS-related complex.

Authors:  J M Gries; I F Troconiz; D Verotta; M Jacobson; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1997-01       Impact factor: 6.875

4.  Population pharmacokinetic data and parameter estimation based on their first two statistical moments.

Authors:  S L Beal
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

5.  Influence of age and gender on the pharmacokinetics and pharmacodynamics of remifentanil. I. Model development.

Authors:  C F Minto; T W Schnider; T D Egan; E Youngs; H J Lemmens; P L Gambus; V Billard; J F Hoke; K H Moore; D J Hermann; K T Muir; J W Mandema; S L Shafer
Journal:  Anesthesiology       Date:  1997-01       Impact factor: 7.892

6.  Population pharmacodynamic modeling and covariate detection for central neural blockade.

Authors:  T W Schnider; C F Minto; H Bruckert; J W Mandema
Journal:  Anesthesiology       Date:  1996-09       Impact factor: 7.892

7.  A population model for the leukopenic effect of etoposide.

Authors:  M O Karlsson; R E Port; M J Ratain; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1995-03       Impact factor: 6.875

8.  Population pharmacokinetics of midazolam in neonates.

Authors:  P Burtin; E Jacqz-Aigrain; P Girard; R Lenclen; J F Magny; P Betremieux; C Tehiry; L Desplanques; P Mussat
Journal:  Clin Pharmacol Ther       Date:  1994-12       Impact factor: 6.875

  8 in total
  123 in total

1.  Target concentration intervention: beyond Y2K.

Authors:  N H Holford
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Likelihood-based diagnostics for influential individuals in non-linear mixed effects model selection.

Authors:  S Sadray; E N Jonsson; M O Karlsson
Journal:  Pharm Res       Date:  1999-08       Impact factor: 4.200

3.  Drug-drug pharmacodynamic interaction detection by a nonparametric population approach. Influence of design and of interindividual variability.

Authors:  Y Merlé; A Mallet; E Schmautz
Journal:  J Pharmacokinet Biopharm       Date:  1999-10

4.  Efficient screening of covariates in population models using Wald's approximation to the likelihood ratio test.

Authors:  K G Kowalski; M M Hutmacher
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

5.  Assessment of actual significance levels for covariate effects in NONMEM.

Authors:  U Wählby; E N Jonsson; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-06       Impact factor: 2.745

6.  Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis.

Authors:  Ulrika Wählby; E Niclas Jonsson; Mats O Karlsson
Journal:  AAPS PharmSci       Date:  2002

7.  Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.

Authors:  Jakob Ribbing; E Niclas Jonsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2004-04       Impact factor: 2.745

8.  Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1.

Authors:  Hee-Doo Yoo; Hea-Young Cho; Sang-No Lee; Hwa Yoon; Yong-Bok Lee
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-24       Impact factor: 2.745

9.  Population pharmacokinetic modelling of Emfilermin (recombinant human leukaemia inhibitory factor, r-hLIF) in healthy postmenopausal women and in infertile patients undergoing in vitro fertilization and embryo transfer.

Authors:  Timothy Goggin; Quyen T X Nguyen; Alain Munafo
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

10.  Bridging the pharmacokinetics and pharmacodynamics of UK-279,276 across healthy volunteers and stroke patients using a mechanistically based model for target-mediated disposition.

Authors:  E Niclas Jonsson; Fiona Macintyre; Ian James; Michael Krams; Scott Marshall
Journal:  Pharm Res       Date:  2005-08-03       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.